Catalog

Melanocortin receptor agonist

The tanning peptide that became an orphan drug for light intolerance.

A stabilized α-MSH analog that darkens skin through MC1R. It is FDA-approved (Scenesse, 2019) as an implant for erythropoietic protoporphyria, a rare disorder where sunlight causes severe pain. It is the molecule grey-market 'melanotan I' claims to be.

1 of 1 claims human-tested · 2 references · FDA-approved

Melanocortin receptor agonist

The FDA-approved libido peptide that skips the vascular route.

A cyclic melanocortin-receptor agonist that acts centrally on sexual desire rather than on blood flow. It is FDA-approved (Vyleesi, 2019) for acquired hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 trials. Structurally it is the near-twin of melanotan II – differing by a C-terminal acid.

2 of 2 claims human-tested · 1 reference · FDA-approved

GLP-1 receptor agonist

The daily GLP-1 that proved the class before semaglutide.

A once-daily acylated GLP-1 analog, FDA-approved for type 2 diabetes (2010) and chronic weight management (2014). It delivers less weight loss than its weekly successors but carries a completed cardiovascular-outcomes trial and a long safety record. Now largely a generic-era benchmark.

2 of 2 claims human-tested · 3 references · FDA-approved

GLP-1 receptor agonist

The molecule that rewrote what weight loss looks like.

A long-acting GLP-1 analog that turns down appetite and slows gastric emptying. It is FDA-approved for type 2 diabetes and chronic weight management, and it carries some of the largest randomized outcome data of any peptide in this catalog.

2 of 2 claims human-tested · 4 references · FDA-approved

Synthetic actin-binding fragment of thymosin β4

The migration-and-angiogenesis peptide behind the recovery hype.

A short synthetic peptide (Ac-LKKTETQ) taken from the actin-binding motif of thymosin β4. Most of the cited healing research actually used the full 43-amino-acid thymosin β4 protein – not this fragment – a distinction the recovery marketing tends to blur.

1 of 3 claims human-tested · 3 references · Research-only

GHRH analog

An FDA-approved GHRH analog that targets visceral fat.

A stabilized growth-hormone-releasing-hormone analog that raises the body's own GH pulses. It is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, backed by controlled trials – the best-evidenced GH-axis peptide here.

2 of 2 claims human-tested · 1 reference · FDA-approved

GIP / GLP-1 dual receptor agonist

Two incretin receptors, one injection, up to ~21% body weight gone.

A once-weekly dual agonist that hits both the GIP and GLP-1 receptors. In its pivotal obesity trial it drove weight loss rivaling bariatric surgery, and it is FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea.

1 of 1 claims human-tested · 3 references · FDA-approved

Growth-hormone fragment

The ‘fat-burning fragment’ the clinic couldn’t confirm.

A synthetic fragment of human growth hormone marketed for lipolysis. It showed fat-metabolism activity in preclinical work, but company-run human weight-loss trials failed to beat placebo – a clean example of a great story meeting hard endpoints.

1 of 2 claims human-tested · 2 references · Research-only

Long-acting amylin analog

The amylin half of the next weight-loss combination.

A once-weekly, lipidated analog of amylin, the pancreatic satiety hormone. Alone it produced weight loss comparable to liraglutide in Phase 2; paired with semaglutide as CagriSema it reached the low twenties in Phase 3. It is not approved in any form.

2 of 2 claims human-tested · 2 references · Research-only

Long-acting GHRH analog

One shot, a week of elevated GH and IGF-1.

A GHRH analog engineered to bind albumin (via a Drug Affinity Complex, or DAC), stretching its action from minutes to days. A human PK study showed sustained GH and IGF-1 elevation; it remains investigational and is not approved for human use. Note the DAC-free version is a different, short-acting molecule.

1 of 1 claims human-tested · 2 references · Research-only

Copper-binding tripeptide

The copper peptide that actually earned its place in skincare.

A naturally occurring tripeptide (Gly-His-Lys) that chelates copper and upregulates collagen, elastin, and repair signaling. It has the strongest human (topical) evidence of the 'cosmeceutical peptide' group – though those trials are small and short – plus a deep preclinical tissue-remodeling literature.

1 of 2 claims human-tested · 2 references · Research-only

Ghrelin-receptor / GH secretagogue

The GH-releasing peptide that became a diagnostic test in Japan.

A synthetic hexapeptide from the growth-hormone-releasing-peptide family that acts on the ghrelin receptor. It produces a strong GH pulse in children and adults, strong enough that Japan uses it as a stimulation test for GH deficiency. It has never been approved as a treatment anywhere.

2 of 2 claims human-tested · 2 references · Approved abroad

Ghrelin-receptor / GH secretagogue

The unnatural peptide that led researchers to ghrelin.

The original growth-hormone-releasing peptide, a synthetic hexapeptide designed in the 1980s before anyone knew what receptor it hit. The hunt for that receptor produced ghrelin. It releases GH in people by every route tested, raises cortisol as well, and was never developed as a drug.

2 of 3 claims human-tested · 3 references · Research-only

Ghrelin-receptor / GH secretagogue

The potent secretagogue with a heart story that never left the lab.

A methylated analog of GHRP-6 and one of the strongest peptide GH secretagogues tested in people. Human studies mapped its GH, prolactin and cortisol effects in detail in the 1990s and early 2000s. The cardioprotective claims that circulate rest on isolated rat hearts.

2 of 3 claims human-tested · 3 references · Research-only

Ghrelin-receptor / GH secretagogue

The selective GH pulse without the cortisol baggage.

A pentapeptide ghrelin-receptor agonist that triggers growth-hormone release with little effect on cortisol or prolactin – the selectivity that made it a research favorite. It works by a different mechanism than the GHRH analogs. Human data are modest but real: a PK study in volunteers and one placebo-controlled surgical trial that found it safe but no better than placebo.

2 of 4 claims human-tested · 3 references · Research-only

Human antimicrobial peptide

Your own antimicrobial peptide, now tested on wounds that won’t close.

The only human cathelicidin, a 37-residue peptide cut from the hCAP18 precursor in skin, airways and immune cells. It kills microbes, recruits immune cells and promotes vessel growth. As a topical drug it has been through a Phase 2b trial in venous leg ulcers that missed its primary endpoint and a small diabetic-foot trial that did not.

2 of 3 claims human-tested · 5 references · Research-only

Melanocortin receptor agonist

The tanning-and-libido peptide that never made it to approval.

A broad-spectrum melanocortin agonist studied for pigmentation and sexual function. Its mechanism is well characterized, but it has no regulatory approval and carries documented safety concerns from unregulated use – a frontier compound with real caveats.

2 of 2 claims human-tested · 2 references · Research-only

Mitochondrial-derived peptide

An ‘exercise mimetic’ written into your mitochondrial DNA.

A 16-amino-acid peptide encoded within mitochondrial DNA that activates AMPK and improves insulin sensitivity – the closest thing to a molecular echo of exercise. The mechanism work is elegant and Western peer-reviewed; human data is early and mostly associative.

1 of 3 claims human-tested · 3 references · Research-only

GIP / GLP-1 / glucagon triple agonist

The triple agonist posting the biggest weight-loss numbers yet.

An investigational once-weekly peptide that activates three metabolic receptors at once. Phase 2 data are striking, but it is not yet approved – this is late-stage clinical promise, not a settled therapy.

1 of 2 claims human-tested · 4 references · Research-only

GHRH analog

The once-approved GHRH analog that lives on in compounding.

The shortest fragment of growth-hormone-releasing hormone that keeps full activity. It was an FDA-approved diagnostic and pediatric treatment (Geref) until the manufacturer discontinued it in 2008, and it is now widely compounded for adult use that was never on the label. The pediatric evidence is real; the adult anti-aging use is not studied.

2 of 2 claims human-tested · 1 reference · Withdrawn

Immunomodulatory peptide

An immune-tuning peptide approved across dozens of countries.

A 28-amino-acid peptide that boosts T-helper and NK-cell responses. Approved in dozens of countries (not the US) for chronic hepatitis and as a vaccine adjuvant, with randomized trial data in viral hepatitis and severe sepsis – the best-replicated of the immune/longevity group.

2 of 2 claims human-tested · 3 references · Approved abroad

Actin-sequestering regenerative peptide

The full-length protein the recovery fragment borrows its name from.

A 43-residue peptide found in nearly every human cell, where it holds actin monomers in reserve and, when released at injury, drives cell migration and repair. It has been through controlled eye trials and is in Phase 3 for dry eye and neurotrophic keratopathy. The grey-market 'TB-500' is a seven-residue fragment of it, not this molecule.

1 of 3 claims human-tested · 4 references · Research-only

Synthetic pentadecapeptide (gastric-derived)

The repair peptide the research world can't stop talking about.

A synthetic 15-amino-acid peptide described as a partial sequence of a protein from gastric juice, studied widely in animal models for tendon, muscle, and gut-lining repair. The preclinical signal is broad but comes largely from one research group – controlled human data is the missing piece.

No human data yet · 2 references · Research-only

Angiotensin IV analog

A nootropic whose key mechanism paper has been retracted.

An orally active, brain-penetrant analog of angiotensin IV developed as a cognitive enhancer. It reversed drug-induced memory deficits in rats and improved an Alzheimer's mouse model, but the paper tying it to the HGF/c-Met growth pathway was retracted in 2025 and the original rat study carries a journal Notice of Concern. There are no human data.

No human data yet · 4 references · Research-only

Pineal tetrapeptide

The telomerase peptide riding decades of Russian longevity claims.

A four-amino-acid peptide reported to activate telomerase and modulate melatonin rhythms. There is a published in-vitro telomerase result, but the lifespan and clinical-longevity claims come almost entirely from older, mostly single-group Russian studies – genuine frontier territory.

No human data yet · 3 references · Research-only

Anti-inflammatory tripeptide

The three-residue tail of α-MSH that calms inflammation.

A tripeptide from the tail end of alpha-MSH, studied for anti-inflammatory activity in the gut and skin. Its mechanism appears to run largely independent of melanocortin receptors; the preclinical data are real, but human trials are absent.

No human data yet · 3 references · Research-only

ACTH (4-10) analog

A nootropic ACTH fragment used clinically in Russia for stroke.

A short peptide derived from ACTH, studied for neuroprotection and cognition and used clinically in Russia (including in stroke). It modulates BDNF and dopamine signaling; the mechanism work is Western-indexed, but the clinical efficacy data is overwhelmingly Russian and unreplicated abroad.

No human data yet · 2 references · Approved abroad

Tuftsin-derived heptapeptide

A Russian anxiolytic peptide with no sedation on the label.

A synthetic analog of the immunopeptide tuftsin, developed in Russia as an anxiolytic and studied for anxiety and cognition. It is a registered prescription drug in its home market; rigorous international trial data is scarce.

No human data yet · 2 references · Approved abroad